Herrera-Lasso Regás Valeria, Dordal Culla María Teresa, Lleonart Bellfill Ramón
Unitat d'Al·lergologia Servei de Medicina Interna, Hospital Universitari de Bellvitge, Barcelona, Spain.
Med Clin (Engl Ed). 2020 Nov 27;155(10):448-453. doi: 10.1016/j.medcle.2020.06.026. Epub 2020 Oct 30.
Currently, there is no treatment approved for COVID-19. Numerous drugs are being used in an empirical manner according to experience and availability. Studies demonstrating their efficacy and safety are still to be published. Thus, it is of vital importance for healthcare workers to be well informed and updated regarding possible immunological and non-immunological adverse effects regarding such treatments. In this narrative revision, the rationale use of these treatments in the SARS-CoV-2 infection is emphasized as well as their most frequently described adverse drug reactions. Drugs that are being essayed to counteract both clinical phases that are thought to take place in the severe stage of this disease are included; an initial phase where a viral infection prevails and a second phase where an inflammatory response takes over. Adverse reactions registered in the Pharmacovigilance Program of our hospital before the onset of this pandemic have also been included.
目前,尚无针对新冠肺炎的获批治疗方法。根据经验和可得性,许多药物正在被凭经验使用。证明其疗效和安全性的研究仍有待发表。因此,医护人员充分了解并及时掌握此类治疗可能产生的免疫和非免疫不良反应至关重要。在这篇叙述性综述中,强调了这些治疗方法在新型冠状病毒感染中的合理应用及其最常描述的药物不良反应。文中纳入了正在试验用于对抗该疾病重症阶段两个临床阶段的药物;第一个阶段以病毒感染为主,第二个阶段以炎症反应为主。还纳入了在本次大流行开始前在我院药物警戒计划中记录的不良反应。